Table 4.

Prevalence of molecular markers of resistance in Day 0 and Day of Failure samples from therapeutic efficacy studies in Guinea, 2016

	Day 0	Day of Failure
pfk13	n = 389	n = 22
Wild-type	380 (98%)	22 (100%)
Mutant	9 (1%)a	0 (0%)

pfmdr1 86 codon	n = 379	n = 18
N	296 (78%)	14 (78%)
Y	59 (16%)	4 (22%)
N/Y	24 (6%)	0 (0%)

pfmdr1 184 codon	n = 379	n = 18
Y	117 (31%)	3 (17%)
F	206 (54%)	14 (78%)
Y/F	56 (15%)	1 (6%)

pfmdr1 1246 codon	n = 370	n = 18
D	363 (98%)	18 (100%)
Y	6 (2%)	0 (0%)
D/Y	1 (0.3%)	0 (0%)

pfmdr1 haplotypesb	n = 362	n = 18
NYD	158 (44%)	4 (22%)
YYD	17 (5%)	0 (0%)
NFD	197 (54%)	11 (61%)
YFD	71 (20%)	4 (22%)
NYY	1 (0.3%)	0 (0%)
YYY	6 (2%)	0 (0%)
NFY	1 (0.3%)	0 (0%)
YFY	0 (0%)	0 (0%)

^aAll 9 samples with polymorphisms not associated with artemisinin resistance: P419S (1), L429L (1), C469C (3), G496G (1), E509E (1), V510V (1), A621A (1)

^bHaplotypes defined at codons 86, 184, and 1246. Samples with multiple haplotypes were included in the numerator for each haplotype